VistaGen Therapeutics Beats EPS Forecast by 10.9%, Revenue Misses by 43.9%
VistaGen Therapeutics recorded a Q3 adjusted loss of $0.45 per share, outperforming the consensus loss estimate of $0.51 by 10.9%. The company reported $0.3 million in revenues, missing estimates by 43.9%, while shares have slid 13.5% year to date as underperformance persists.
1. Q3 Earnings Results
VistaGen Therapeutics delivered an adjusted loss of $0.45 per share for Q3 fiscal 2026, surpassing the consensus loss estimate of $0.51 by 10.9%. This compares to a $0.46 per-share loss in the year-ago quarter, marking a modest improvement in cost controls or expense management.
2. Revenue Performance
Total revenues for the quarter were $0.3 million, up from $0.23 million in Q3 2025 but 43.9% below analyst forecasts. The shortfall underscores ongoing challenges in commercializing its clinical-stage pipeline and generating material product sales.
3. Market Reaction and Outlook
Shares of VistaGen have declined 13.5% year to date, versus a 1.4% gain in the S&P 500, as investors weigh mixed financial metrics. Consensus estimates call for a Q4 adjusted loss of $0.51 per share on $0.4 million in revenue, with full-year fiscal 2026 forecasts of a $2.03 loss on $0.97 million in sales.